Olaparib (AZD2281)

Name: Olaparib (AZD2281)
Brand: Selleck Chemicals
SKU: S1060
Rating: 5 (493 reviews)

For research use only.

Catalog No.S1060 Synonyms: Ku-0059436

493 publications

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Selleck's Olaparib (AZD2281) has been cited by 493 publications

Cancer Cell, 2020, 15 pii: S1535-6108(20)30164-1

PubMed: 32359397 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):157-167

PubMed: 32004442 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):722-737

PubMed: 31015319 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Nat Biotechnol, 2018, 36(1):95-102

PubMed: 29176614 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Genet, 2018, 50(8):1086-1092

PubMed: 30013182 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Cancer Cell, 2018, 33(2):202-216

PubMed: 29358035 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Cell Metab, 2018, 1;27(5):1067-1080.e5

PubMed: 29685734 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )

Nat Med, 2016, 22(2):194-201

PubMed: 26779812 ( click the link to review the publication )
Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell, 2014, 8;157(4):882-896.

PubMed: 24813611 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 13;145(4):529-42.

PubMed: 21565612 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(1):87-96

PubMed: 31915374 ( click the link to review the publication )

Nat Commun, 2020, 5;11(1):2834

PubMed: 32503981 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2147

PubMed: 32358495 ( click the link to review the publication )

Nat Commun, 2020, 26;11(1):2641

PubMed: 32457376 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2573

PubMed: 32444794 ( click the link to review the publication )

Nat Commun, 2020, 20;11(1):1884

PubMed: 32313004 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2174

PubMed: 32358582 ( click the link to review the publication )

Sci Adv, 2020, 22;6(17):eaaz3221

PubMed: 32494639 ( click the link to review the publication )

Nucleic Acids Res, 2020, 15;gkaa508

PubMed: 32542389 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa038

PubMed: 31980815 ( click the link to review the publication )

Nucleic Acids Res, 2020, 16 pii: gkaa255

PubMed: 32297953 ( click the link to review the publication )

J Thorac Oncol, 2020, 10.1016/j.jtho.2020.01.012

PubMed: 32004714 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2000

PubMed: 31900275 ( click the link to review the publication )

Dev Cell, 2020, 20;53(2):240-252

PubMed: 32197067 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )
Cancer Res, 2020, 10.1158/0008-5472.CAN-19-2069

PubMed: 32019870 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-2739

PubMed: 32193285 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.240713

PubMed: 32079692 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):9

PubMed: 32005272 ( click the link to review the publication )

Oncogene, 2020, 39(14):2905-2920

PubMed: 32029902 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1175-x

PubMed: 32001817 ( click the link to review the publication )

Cancer Lett, 2020, 469:78-88

PubMed: 31629931 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):3

PubMed: 31898520 ( click the link to review the publication )

Cancers (Basel), 2020, 7;12(5) pii: E1180

PubMed: 32392755 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32033118 ( click the link to review the publication )

BMC Biol, 2020, 30;18(1):36

PubMed: 32228693 ( click the link to review the publication )

J Clin Med, 2020, 30;9(4)

PubMed: 32235451 ( click the link to review the publication )

Cells, 2020, 8;9(4)

PubMed: 32276472 ( click the link to review the publication )

Cells, 2020, 7;9(2)

PubMed: 32046043 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-0926

PubMed: 32127465 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):552-563

PubMed: 31619462 ( click the link to review the publication )

Gynecol Oncol, 2020, 157(1):222-233

PubMed: 31987601 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(4)

PubMed: 32053991 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2585

PubMed: 32066817 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )
Oncol Rep, 2020, 43(5):1397-1412

PubMed: 32323799 ( click the link to review the publication )

Eur J Pharmacol, 2020, 15;877:173091

PubMed: 32234526 ( click the link to review the publication )

Biochemistry, 2020, 10.1021/acs.biochem.0c00256

PubMed: 32357296 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 85(2):273-284

PubMed: 31907647 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 28

PubMed: 32468080 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 522(4):945-951

PubMed: 31806370 ( click the link to review the publication )

J Radiat Res, 2020, 23;61(2):177-186

PubMed: 31976528 ( click the link to review the publication )

J Radiat Res, 2020, 22;61(3):352-367

PubMed: 32329510 ( click the link to review the publication )

Int J Radiat Biol, 2020, 10.1080/09553002.2020.1711461

PubMed: 31914341 ( click the link to review the publication )

Oncol Lett, 2020, 19(4):2629-2638

PubMed: 32218813 ( click the link to review the publication )

Cancer Res, 2020, 10.1158

PubMed: 32127357 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):648-661

PubMed: 32195033 ( click the link to review the publication )

Biol Blood Marrow Transplant, 2020, 10.1016

PubMed: 32194286 ( click the link to review the publication )

Theranostics, 2020, 10(7):3351-3365

PubMed: 32194873 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(3):311-318

PubMed: 30804502 ( click the link to review the publication )

Sci Transl Med, 2019, 11(492)

PubMed: 31092693 ( click the link to review the publication )

Cell Res, 2019, 29(3):233-247

PubMed: 30728452 ( click the link to review the publication )

Nat Microbiol, 2019, 4(11):1872-1884

PubMed: 30988430 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.026

PubMed: 31759821 ( click the link to review the publication )

Mol Cell, 2019, 73(4):845-856

PubMed: 30712989 ( click the link to review the publication )

Mol Cell, 2019, 76(3):473-484

PubMed: 31494034 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.09.024

PubMed: 31653568 ( click the link to review the publication )

Mol Cell, 2019, 73(5):885-899

PubMed: 30686591 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1286-1298

PubMed: 31473101 ( click the link to review the publication )
Mol Cell, 2019, 73(2):224-237

PubMed: 30554948 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.008

PubMed: 31676232 ( click the link to review the publication )

Mol Cell, 2019, 73(6):1267-1281

PubMed: 30704900 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4632

PubMed: 31604914 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4363

PubMed: 31554794 ( click the link to review the publication )

J Clin Invest, 2019, 129(3):1211-1228

PubMed: 30589644 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5654

PubMed: 31827085 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5296

PubMed: 31757951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2849

PubMed: 31253762 ( click the link to review the publication )

Nat Commun, 2019, 10(1):241

PubMed: 30651562 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):65

PubMed: 30622262 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5661

PubMed: 31827092 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5501

PubMed: 31796734 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(11):5634-5647

PubMed: 31006810 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz820

PubMed: 31566235 ( click the link to review the publication )

Nucleic Acids Res, 2019, 19;47(16):8502-8520

PubMed: 31616951 ( click the link to review the publication )

EMBO J, 2019, 15;38(16):e101284

PubMed: 31294866 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6127-6140

PubMed: 31409614 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6206-6216

PubMed: 31409613 ( click the link to review the publication )
EMBO Mol Med, 2019, 11(7):e9982

PubMed: 31273933 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2549

PubMed: 31852834 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31439587 ( click the link to review the publication )

Genes Dev, 2019, 33(5-6):333-347

PubMed: 30796017 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

EMBO Rep, 2019, 20(5)

PubMed: 30940648 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32670

PubMed: 31495919 ( click the link to review the publication )

Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

Oncogene, 2019, 38(2):180-193

PubMed: 30093630 ( click the link to review the publication )

J Med Chem, 2019, 62(11):5330-5357

PubMed: 31042381 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627329 ( click the link to review the publication )

Cancers (Basel), 2019, 12(1)

PubMed: 31877762 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):165

PubMed: 31775874 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )
FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.10.013

PubMed: 31735695 ( click the link to review the publication )

Stem Cells, 2019, 37(1):42-53

PubMed: 30353615 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Transl Res, 2019, 10.1016/j.trsl.2019.10.003

PubMed: 31707040 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(11):2442-2455

PubMed: 31815045 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(3):608-618

PubMed: 30949414 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Front Oncol, 2019, 9:1406

PubMed: 31921663 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):1064-1075

PubMed: 30663191 ( click the link to review the publication )

Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31795418 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(33):12459-12471

PubMed: 31248990 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )
Breast Cancer Res Treat, 2019, 176(1):109-117

PubMed: 30989461 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Virology, 2019, 537:254-262

PubMed: 31539774 ( click the link to review the publication )

Prostate, 2019, 79(4):390-402

PubMed: 30520109 ( click the link to review the publication )

Cell Cycle, 2019, 1-14

PubMed: 31238782 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):829

PubMed: 31438892 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 10.1007/s00432-019-03097-6

PubMed: 31786739 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2528

PubMed: 31512408 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):871-878

PubMed: 31075528 ( click the link to review the publication )

J Gynecol Oncol, 2019, 30(2):e26

PubMed: 30740957 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223725

PubMed: 31596905 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.050

PubMed: 31753490 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Cell Biochem, 2019, 457(1-2):41-49

PubMed: 30993494 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Am J Vet Res, 2019, 80(7):663-669

PubMed: 31246122 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2722-2737

PubMed: 31105872 ( click the link to review the publication )
Nucleic Acids Res, 2019, 47(20):10662-10677

PubMed: 31586400 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Commun Biol, 2019, 2:335

PubMed: 31508509 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:14

PubMed: 30993195 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(17):9132-9143

PubMed: 31329989 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3555-3564

PubMed: 31002368 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(2):162-174

PubMed: 29335528 ( click the link to review the publication )

Mol Cell, 2018, 71(1):11-24

PubMed: 29937341 ( click the link to review the publication )

Mol Cell, 2018, 72(4):636-649

PubMed: 30293785 ( click the link to review the publication )

Mol Cell, 2018, 71(6):897-910

PubMed: 30122534 ( click the link to review the publication )

Mol Cell, 2018, 72(1):127-139

PubMed: 30244837 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4525-4542

PubMed: 30222135 ( click the link to review the publication )

Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3982

PubMed: 30266942 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1849

PubMed: 29748565 ( click the link to review the publication )

Nat Commun, 2018, 9(1):176

PubMed: 29330466 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2016

PubMed: 29789535 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nat Commun, 2018, 9(1):144

PubMed: 29321523 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403

PubMed: 30257201 ( click the link to review the publication )
Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 23(11):3127-3136

PubMed: 29898385 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.37818

PubMed: 30088474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.38771

PubMed: 29985131 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )

Cancer Lett, 2018, 423:60-70

PubMed: 29526801 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

PLoS Pathog, 2018, 14(11):e1007394

PubMed: 30395643 ( click the link to review the publication )

Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Int J Nanomedicine, 2018, 13:8063-8074

PubMed: 30555227 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 150:24-34

PubMed: 29355504 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:719-728

PubMed: 29524880 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):96-106

PubMed: 29420256 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1285-1296

PubMed: 29479816 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2261-2269

PubMed: 29512738 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(3):e0194611

PubMed: 29590171 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190717

PubMed: 29298345 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0207934

PubMed: 30543656 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

SLAS Discov, 2018, 23(6):545-553

PubMed: 29676938 ( click the link to review the publication )

Blood Cells Mol Dis, 2018, 71:23-28

PubMed: 29422232 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(5):2417-2431

PubMed: 29361132 ( click the link to review the publication )

Oncotarget, 2018, 9(99):37319-37332

PubMed: 30647872 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:12-24

PubMed: 29807321 ( click the link to review the publication )

Oncotarget, 2018, 9(98):37080-37096

PubMed: 30647846 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(2):804-822

PubMed: 29216372 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(18):9537-9549

PubMed: 30137419 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )
RNA Biol, 2018, 15(11):1420-1432

PubMed: 30362859 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10585-10605

PubMed: 29535829 ( click the link to review the publication )

Sci Transl Med, 2017, 9(375)

PubMed: 28148839 ( click the link to review the publication )

Circ Res, 2017, 120(12):1889-1902

PubMed: 28356339 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 67(3):374-386

PubMed: 28735897 ( click the link to review the publication )

Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )

Mol Cell, 2017, 68(2):414-430

PubMed: 29053959 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(11):902-910

PubMed: 28991266 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

J Clin Invest, 2017, 127(8):3013-3027

PubMed: 28691929 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2392-2406

PubMed: 28481221 ( click the link to review the publication )

Nat Commun, 2017, 8(1):859

PubMed: 29038466 ( click the link to review the publication )

Nat Commun, 2017, 8:14632

PubMed: 28272405 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3906-3921

PubMed: 28160604 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1398-1414

PubMed: 28729482 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):514-522

PubMed: 28034904 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Genes Dev, 2017, 31(1):46-58

PubMed: 28115467 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.30523

PubMed: 29106372 ( click the link to review the publication )
Oncogene, 2017, 36(33):4682-4691

PubMed: 28394338 ( click the link to review the publication )

Cancer Lett, 2017, 398:1-11

PubMed: 28385602 ( click the link to review the publication )

Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):63

PubMed: 28482906 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):2022-2034

PubMed: 28619759 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):45-58

PubMed: 27671334 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12876

PubMed: 28993682 ( click the link to review the publication )

Virology, 2017, 507:220-230

PubMed: 28456021 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(9):694-704

PubMed: 28886275 ( click the link to review the publication )

Cell Cycle, 2017, 16(11):1128-1135

PubMed: 28463527 ( click the link to review the publication )

Transl Oncol, 2017, 10(2):190-196

PubMed: 28182994 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(11):2705-2716

PubMed: 28394191 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(1):211-217

PubMed: 28487110 ( click the link to review the publication )

Int J Med Sci, 2017, 14(12):1292-1300

PubMed: 29104487 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )
Nucleic Acids Res, 2017, 45(18):10614-10633

PubMed: 28977657 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13223-13239

PubMed: 28099939 ( click the link to review the publication )

Tumour Biol, 2017, 39(10):1010428317713390

PubMed: 29064327 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94505-94518

PubMed: 29212245 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29963-29975

PubMed: 28415784 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3844-3859

PubMed: 28158503 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1467-1472

PubMed: 29296788 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31815-31829

PubMed: 28415632 ( click the link to review the publication )

Oncotarget, 2017, 8(25):40152-40168

PubMed: 27374179 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )

J Clin Invest, 2016, 126(8):2903-18

PubMed: 27454287 ( click the link to review the publication )

Nat Commun, 2016, 7:13837

PubMed: 27958275 ( click the link to review the publication )

Nat Commun, 2016, 7:12425

PubMed: 27498558 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(5):2546-2557

PubMed: 27965414 ( click the link to review the publication )

EMBO J, 2016, 35(14):1488-503

PubMed: 27225932 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2778-90

PubMed: 27197267 ( click the link to review the publication )

Theranostics, 2016, 6(11):1821-32

PubMed: 27570553 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )
Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.13620

PubMed: 27336789 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(6):1219-1228

PubMed: 26880244 ( click the link to review the publication )

Diabetologia, 2016, 59(11):2360-2368

PubMed: 27539148 ( click the link to review the publication )

Br J Cancer, 2016, 114(7):777-86

PubMed: 26964031 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Gynecol Oncol, 2016, 142(2):323-31

PubMed: 27282964 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Mediators Inflamm, 2016, 2016:1984703

PubMed: 27524861 ( click the link to review the publication )

Cell Cycle, 2016, 15(22):3105-3114

PubMed: 27686740 ( click the link to review the publication )

BMC Cancer, 2016, 16:621

PubMed: 27515310 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):851

PubMed: 27816051 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

BMC Cancer, 2016, 16:550

PubMed: 27465688 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Bioorg Med Chem, 2016, 24(5):1071-8

PubMed: 26833244 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1516-26

PubMed: 26869042 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146031

PubMed: 26730949 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):234-240

PubMed: 27425251 ( click the link to review the publication )

Anal Biochem, 2016, 503:58-64

PubMed: 27036617 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Target Oncol, 2016, 11(5):655-665

PubMed: 27188390 ( click the link to review the publication )
Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):772-81

PubMed: 27020103 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

Oncotarget, 2016, 7(9):9732-41

PubMed: 26799421 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2016, 19(1):16-23

PubMed: 26805733 ( click the link to review the publication )

Oncotarget, 2016, 7(22):32980-9

PubMed: 27145275 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75551-75560

PubMed: 27705909 ( click the link to review the publication )

Mol Cancer, 2015, 14:114

PubMed: 26041471 ( click the link to review the publication )

Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

PLoS Genet, 2015, 11(7):e1005384

PubMed: 26181065 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11):2560-8

PubMed: 26351319 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2818-30

PubMed: 26438158 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(11):1465-77

PubMed: 26217019 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(10):1389-97

PubMed: 26116172 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

J Transl Med, 2015, 13:225

PubMed: 26169874 ( click the link to review the publication )

J Transl Med, 2015, 13:233

PubMed: 26183824 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )
Sci Rep, 2015, 5:10129

PubMed: 25984718 ( click the link to review the publication )

Front Microbiol, 2015, 6:878

PubMed: 26379653 ( click the link to review the publication )

Biochem J, 2015, 469(2):189-98

PubMed: 25940138 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):752-67

PubMed: 26069190 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3261-9

PubMed: 26317799 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

BMC Cancer, 2015, 15:89

PubMed: 25884663 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 460(2):183-90

PubMed: 25767076 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:3047-54

PubMed: 26543375 ( click the link to review the publication )

Mol Cell Biochem, 2015, 400(1-2):153-62

PubMed: 25404465 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

Oncol Lett, 2015, 9(2):757-761

PubMed: 25621047 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

Nucleic Acids Res, 2015, 43(14):6934-44

PubMed: 26130715 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43679-97

PubMed: 26544897 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

DNA Repair (Amst), 2015, 35:106-15

PubMed: 26519824 ( click the link to review the publication )

DNA Repair (Amst), 2015, 26:23-9

PubMed: 25541391 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )
Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

Sci Transl Med, 2014, 6(222):222ra18

PubMed: 24500406 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3061-74

PubMed: 24911143 ( click the link to review the publication )

Nat Commun, 2014, 5:3946

PubMed: 24867710 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Cell Death Differ, 2014, 21(2):258-69

PubMed: 24121277 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

PLoS Genet, 2014, 10(10):e1004654

PubMed: 25275444 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )
Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Radiother Oncol, 2014, 113(3):345-51

PubMed: 25467050 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )

Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):735-44

PubMed: 24378347 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1708-16

PubMed: 24675890 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Oncol Lett, 2014, 8(3):1222-1228

PubMed: 25120693 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):347-54

PubMed: 23396353 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )
Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )

FASEB J, 2013, 27(6):2316-27

PubMed: 23444429 ( click the link to review the publication )

PLoS Genet, 2013, 9(6):e1003531

PubMed: 23785295 ( click the link to review the publication )

Mol Oncol, 2013, 7(3):567-79

PubMed: 23415752 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Neoplasia, 2013, 15(6):600-8

PubMed: 23730208 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

J Mass Spectrom, 2013, 48(12):1285-90

PubMed: 24338883 ( click the link to review the publication )

DNA Repair (Amst), 2013, 12(6):394-402

PubMed: 23570906 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10268-82

PubMed: 23997120 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

PLoS Genet, 2012, 8(3):e1002574

PubMed: 22412391 ( click the link to review the publication )
Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

J Biol Chem, 2011, 286(14):12157-65

PubMed: 21285347 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETaUmo1KGR?		MmjsTWM2OD13LkewOUAh\|ryPIB?=	MWmxPFU2QTZzMx?=
KP6.3	NVPTeHA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUK0JIQ>		M{XyfGlEPTB;MUCuOFI5KM7:TTC=	MkHKNVg2PTl4MUO=
KP7.7	M3zUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmLXOEBl		Mn\oTWM2OD13NzDuUUA>	NUPTeWRVOTh3NUm2NVM>
KB2P3.4	M1TVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1fUXVQh\A>?		MYXJR\|UxRTF{NDDNJC=>	MYexPFU2QTZzMx?=
KB2P1.21	NGPKS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1WyS\|Qh\A>?		NVnOclN{UUN3ME24PVA4KG6PIB?=	NGfIclEyQDV3OU[xNy=>
U373-MG	M4DDc2N6fG:2b4jpZ{BCe3OjeR?=	NH7xTogyKM7:TTC=	M3zWeFI1KGh?		M{i4XGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl?	MX2xPFk2PDdzMh?=
T98G	M4i5Z2N6fG:2b4jpZ{BCe3OjeR?=	M1HmO\|Eh\|ryPIB?=	MkO5NlQhcA>?		MlHETY5kemWjc3XzJJJi\GmjdHnvckB{\W6\|aYTpeol1gQ>?	M1\SRVE5QTV2N{Gy
U87-MG	NXH6cINjS3m2b4TvfIlkKEG\|c3H5	MVexJO69VSB?	MY[yOEBp		NHfwcHdKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7	NILXO4IyQDl3NEexNi=>
UVW	MWTDfZRwfG:6aXOgRZN{[Xl?	NEXOSnA2ODBibl2=	NV23U5NwOjRiaB?=		NW\KUGNQUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	NXX6bGtEOTh7NUS3NVI>
HeLa	NX3KTGFkTnWwY4Tpc44hSXO\|YYm=	M3HvflUxOCCwTR?=	M2jCeVQhcA>?		MUjDZZV{\XNiYTDtc4Rme3RiZHXsZZkhcW5icnXqc4lvcW6pIH;mJJJi\GmjdHnvck1qdmS3Y3XkJGRPSSCkcnXhb5M>	NYjZ[\|hNOTh7NUS3NVI>
HeLa	MXnGeY5kfGmxbjDBd5NigQ>?	MkDjNUDPxE1i	NWH0bmRkOjRiaB?=		MWfFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>?	NILGZoUyQDl3NEexNi=>
T98G	M3OycGZ2dmO2aX;uJGF{e2G7	M4n1c\|Eh\|ryPIB?=	NHjvPGozPCCq		MnTaSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG\|ZTDhdpJme3R?	MoXmNVg6PTR5MUK=
L3	NH;5NnVEgXSxdH;4bYMhSXO\|YYm=	NVfLPJZJPSEQvF2g	MlnTPVYhcA>?	NXvLVI9oTE2VTx?=	M1ryc3Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=>	M1vsd\|IxOTJ2NEW5
Granta-519	NH;6bW9EgXSxdH;4bYMhSXO\|YYm=	MWS1JO69VSB?	M1P0NFk3KGh?	NXPqXWVQTE2VTx?=	NHe3NVNUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	MX:yNFEzPDR3OR?=
BT	MUPDfZRwfG:6aXOgRZN{[Xl?	MWW1JO69VSB?	NVruSpBQQTZiaB?=	MYPEUXNQ	MnLJV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NW[y[WZnOjBzMkS0OVk>
UPN2	NVK1WpBiS3m2b4TvfIlkKEG\|c3H5	M160Z\|Uh\|ryPIB?=	M{Xa[lk3KGh?	NED1V\|lFVVOR	NUPhN4tEW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	MoLXNlAyOjR2NUm=
HBL-2	MWHDfZRwfG:6aXOgRZN{[Xl?	MljwOUDPxE1i	M1\hV\|k3KGh?	M{CyTmROW09?	MVzTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt	MkjoNlAyOjR2NUm=
JVM-2	NWqxZ5g2S3m2b4TvfIlkKEG\|c3H5	NXm2c\|k3PSEQvF2g	M4nRO\|k3KGh?	NHnYdVJFVVOR	NUjwW5dtW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	NEPS[mEzODF{NES1PS=>
Z138	MlLzR5l1d3SxeHnjJGF{e2G7	MVu1JO69VSB?	NWO4TXVHQTZiaB?=	MkOxSG1UVw>?	NX\4U5dWW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=	MYqyNFEzPDR3OR?=
RWPE	NFnmOnNKdn[jc3n2[UBCe3OjeR?=	M2f2N\|I2KM7:TR?=	M3:xO\|Q5KGh?	MYLEUXNQ	MoXqV4lodmmoaXPhcpRtgSC{ZXT1Z4V{KEWURz3kdol3\W5iY3XscEBqdn[jc3nvci=>	MWqyNVU4PTh4NR?=
VCaP	MmXlTY53[XOrdnWgRZN{[Xl?	NXHh[mNuOjVizszN	NULx[WhLPDhiaB?=	NGW2dIdFVVOR	NEfRcXhUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v	NHjTZnAzOTV5NUi2OS=>
Mouse H2AX−/− ES Cells	NF2weWVEgXSxdH;4bYMhSXO\|YYm=	NGLVZlczNjVizszN	NWD5cYZZOjBiaB?=		Mk\DV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs	NGHO[m4zOzN3NUS4PS=>
Mouse ATM−/− ES Cells	MXnDfZRwfG:6aXOgRZN{[Xl?	M2DX[\|IvPSEQvF2=	M{KzSFIxKGh?		MUfTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=	MoHyNlM{PTV2OEm=
H1650	M3iwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKyNEDPxE1?	MkTuNVQ1KGh?		Mk[zTWM2OD1zNT60O{DPxE1?	NV[zXnNzOjN{M{m4NFk>
H1650PTEN+	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml2yNlAh\|ryP	NIq0UVEyPDRiaB?=		NEH0T29KSzVyPUWwMlg{KM7:TR?=	NF7hV\|czOzJ\|OUiwPS=>
PC-9	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEmyNWszOCEQvF2=	M4n5fFE1PCCq		M4fjT2lEPTB;NT64PEDPxE1?	NE\yUG0zOzJ\|OUiwPS=>
PC-9PTEN−	NWjpV3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2S4R\|IxKM7:TR?=	NF;peZMyPDRiaB?=		NIWzU2lKSzVyPU[uOVIh\|ryP	MVmyN\|I{QThyOR?=
MDA-MB-231	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITPUIY2KGSjeR?=		NFHzS3RKSzVyPU[uPUDPxE1?	NH\wTZkzOzd4MES5Oi=>
MDA-MB-468	NWX0VJlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoDROUBl[Xl?		NUS1b5Z5UUN3ME21MlAh\|ryP	NGXzWY4zOzd4MES5Oi=>
BT20	M3j1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1LjTlUh\GG7		MmH3TWM2OD15Lkeg{txO	NYDBU4JQOjN5NkC0PVY>
HCC1143	NH7ZWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnnmOUBl[Xl?		NI\6OVRKSzVyPUGxMlEh\|ryP	NGKyZmozOzd4MES5Oi=>
HCC1937	NWXEcmZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mo\LOUBl[Xl?		NVjZb3QxUUN3ME2xNk43KM7:TR?=	M17nU\|I{PzZyNEm2
Hs578t	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEjVNpM2KGSjeR?=		M2[wcWlEPTB;NT62JO69VQ>?	M362UlI{PzZyNEm2
Hs578t(si)	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MorCOUBl[Xl?		NV;tbJV5UUN3ME23MlUh\|ryP	NVzvXFJPOjN5NkC0PVY>
BT474	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXiwS\|gzPSCmYYm=		NV3XZo5FUUN3ME2xPU45KM7:TR?=	M13VVFI{PzZyNEm2
JIMT1	NET5OHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVPH[YRFPSCmYYm=		NXnwcpBFUUN3ME23Mlch\|ryP	MYSyN\|c3ODR7Nh?=
SKBR3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{LLT\|Uh\GG7		MX\JR\|UxRTFzLkGg{txO	MWOyN\|c3ODR7Nh?=
SUM159	M2rMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUnlO3ZtPSCmYYm=		NVrZTm1ZUUN3ME20MlIh\|ryP	Mnr6NlM4PjB2OU[=
CAMA1	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYjpVVJyPSCmYYm=		MnLOTWM2OD1zNT64JO69VQ>?	NU\yTJZrOjN5NkC0PVY>
MCF7	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX:1JIRigQ>?		MnHBTWM2OD13Lkig{txO	NWjTU2lROjN5NkC0PVY>
T47D	NWXNemZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX[1JIRigQ>?		MXLJR\|UxRTlwNjFOwG0>	M4i1bVI{PzZyNEm2
HCT116	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEn4dVcyODBizszN	M3q3WlQ5KGh?	MlLOSG1UVw>?	MoHOTWM2OD1{LkWg{txOKA>?	M1vwflI1PTd5OUSx
SW1116	M1TKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\DNVAxKM7:TR?=	MVG0PEBp	M3;BemROW09?	NELPVmFKSzVyPUGwNEDPxE1?	M{LqU\|I1PTd5OUSx
HT29	M{\vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWr6cW51OTByIN88US=>	NVzPTnNxPDhiaB?=	Mn[xSG1UVw>?	MnjKTWM2OD1zND63JO69VQ>?	MUmyOFU4Pzl2MR?=
LoVo	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfxWXM3OTByIN88US=>	NFzBPYs1QCCq	M1\GVmROW09?	MVXJR\|UxRTF\|LkSg{txO	MlLKNlQ2Pzd7NEG=
HCT-15	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DwblExOCEQvF2=	M2mzeFQ5KGh?	M4Pyd2ROW09?	M2\nZWlEPTB;MUCg{txO	MYeyOFU4Pzl2MR?=
SW48	M1uwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HPblExOCEQvF2=	NXPWNm1UPDhiaB?=	M2LJe2ROW09?	M2nJR2lEPTB;OT61JO69VQ>?	MYWyOFU4Pzl2MR?=
C-1	NHeyOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rhTFExOCEQvF2=	NWXPPYp1PDhiaB?=	NYTLTII3TE2VTx?=	NELpc3dKSzVyPUeuOkDPxE1?	MnfsNlQ2Pzd7NEG=
RKO	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1T0N\|ExOCEQvF2=	M4jvXFQ5KGh?	M2C0XmROW09?	MULJR\|UxRTVwOTFOwG0>	NXfuRpN{OjR3N{e5OFE>
HCT116	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPzNVAxKM7:TR?=	M{i3clQ5KGh?	Mk\MSG1UVw>?	MnziVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MmK4NlQ2Pzd7NEG=
SW1116	NGSzdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITJO5QyODBizszN	NXTBOnlrPDhiaB?=	NXrUOoVDTE2VTx?=	Mn;XVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MkHMNlQ2Pzd7NEG=
HT29	MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3O5UFExOCEQvF2=	NX3STodSPDhiaB?=	M2rHRWROW09?	M1TySXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	MmTmNlQ2Pzd7NEG=
LoVo	NGTJNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrTNZgyODBizszN	MVO0PEBp	Mkj6SG1UVw>?	MX7Qc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	NHT6ZnYzPDV5N{m0NS=>
SW48	M4Dn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PGPVExOCEQvF2=	MnjiOFghcA>?	NUjpbow1TE2VTx?=	NVXiUI9HWG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	MXyyOFU4Pzl2MR?=
C-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUixNFAh\|ryP	M17qd\|Q5KGh?	NV\6c2o6TE2VTx?=	NV;VfmQ3WG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	M2ezWFI1PTd5OUSx
RKO	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HOVFExOCEQvF2=	MofxOFghcA>?	MXLEUXNQ	MnfzVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	M3rDN\|I1PTd5OUSx
HCT116	NFTVfVJHfW6ldHnvckBCe3OjeR?=	NFHmXnkyOCCwTR?=	NFS1TmQyOiCq	NVK3W2MzTE2VTx?=	NFHjendKdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	M1nZbFI1PTd5OUSx
HT29	NUfscGFpTnWwY4Tpc44hSXO\|YYm=	MmHDNVAhdk1?	NWjjU4VuOTJiaB?=	MmP3SG1UVw>?	MmXETY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6	NFWxfIwzPDV5N{m0NS=>
TE-6	NGHCXpBHfW6ldHnvckBCe3OjeR?=	MXy1JO69VSB?	MlniNVIhcA>?	Mn;4SG1UVw>?	NEfjZpJKdmS3Y3XzJGczN01iYYLy[ZN1	M1TtfFI1OjF7MU[0
TE-6	MYHGeY5kfGmxbjDBd5NigQ>?	M2fWbFUh\|ryPIB?=	NGPtXZgzPCCq	Ml[3SG1UVw>?	NVHZcJE3UW6lcnXhd4V{KGmwIHTveYJt\SC\|dILhcoQh[nKnYXvzJEhFW0K\|KR?=	NFfGb3AzPDJzOUG2OC=>
Hep3B	MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXS0NEDPxE1i	NVm4WIZ4PzJiaB?=	Mn\SSG1UVw>?	M1Lpc3N6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS	NHnOTWwzPTB5Mke1Ni=>
Huh7	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXWXng1OCEQvF2g	M2ryO\|czKGh?	M{npSGROW09?	M3\wb3N6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS	NVTjU\|FFOjVyN{K3OVI>
Hep3B	NXz1UZhITnWwY4Tpc44hSXO\|YYm=	NH7OXpY1OCEQvF2g	NWryU4EyOjRiaB?=	NHi1VXdFVVOR	Ml[yTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT	NYe2XGRsOjVyN{K3OVI>
Huh7	NYPYTWd{TnWwY4Tpc44hSXO\|YYm=	Mlq5OFAh\|ryPIB?=	MlrZNlQhcA>?	MXfEUXNQ	M3q5Xmlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?=	M3TIWlI2ODd{N{Wy
Hep3B	NVy2emVzTnWwY4Tpc44hSXO\|YYm=	NVzLfFY6PDBizszNJC=>	NILCXnYzPCCq	M1m0RmROW09?	MlHKTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT	NGjjTWEzPTB5Mke1Ni=>
Huh7	NXnmPJBUTnWwY4Tpc44hSXO\|YYm=	NGe4ZpY1OCEQvF2g	NXnoRpVlOjRiaB?=	NYjMR\|RNTE2VTx?=	MnG5TY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT	MX6yOVA4Ojd3Mh?=
SGC-7901	NILnUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnGN\|DDqM7:TR?=	NETGPVI1QCCq	MoLOSG1UVw>?	NYfaWmp4SmyxY3ugc5hidGmybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRp	MYiyOVc3PzB5Nh?=
COLO-800	NWT6[W9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfWXW9NUUN3ME2wMlQ1OTZ2IN88US=>	NEjxRYtUSU6JRWK=
EoL-1-	NHnxdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\BTWM2OD1yLkW2OFQ3KM7:TR?=	M2XLVXNCVkeHUh?=
NCI-H209	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTycplKSzVyPUCuPVE2PTZizszN	M4jzVnNCVkeHUh?=
ES1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTFwMUG0NFgh\|ryP	NWnhXlY6W0GQR1XS
NKM-1	NWC3WnZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTFwMkWzOFch\|ryP	M4j5NnNCVkeHUh?=
NTERA-S-cl-D1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3QfYNKSzVyPUGuN\|M{PDFizszN	MWDTRW5ITVJ?
MHH-ES-1	MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHMTWM2OD1zLk[yNFY4KM7:TR?=	NHLGN5BUSU6JRWK=
ES8	NFe2TFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHm1c41KSzVyPUGuO\|I1OTRizszN	NXe2bXZlW0GQR1XS
NCI-H720	NHHGZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2C4[GlEPTB;Mj6yNFY6QSEQvF2=	NEjlWlRUSU6JRWK=
EW-3	NXrU[2wzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJwMke1N\|Qh\|ryP	NF\tNmJUSU6JRWK=
D-566MG	NVTsNYlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXQVFRKSzVyPUKuOFQ2PjhizszN	Mk\MV2FPT0WU
697	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fETWlEPTB;Mj64OFE4OyEQvF2=	MkjUV2FPT0WU
ES5	NE\C[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITjV4VKSzVyPUKuPFgyQDlizszN	M1m5enNCVkeHUh?=
COLO-684	NXX0[2NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPITWM2OD1\|LkWxOlk3KM7:TR?=	MWrTRW5ITVJ?
ML-2	MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rvbGlEPTB;Mz62NFA2QCEQvF2=	MXTTRW5ITVJ?
MC-IXC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvXTWM2OD1\|Lk[zN\|k{KM7:TR?=	MkTHV2FPT0WU
DB	NHSwdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHTdJVKSzVyPUOuOlU1PDhizszN	Mn74V2FPT0WU
HCC2218	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHVWZpkUUN3ME2zMlc{OTB\|IN88US=>	MULTRW5ITVJ?
NCI-H510A	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jlcGlEPTB;Mz64NlczPCEQvF2=	MVPTRW5ITVJ?
NCI-H526	NUG3WY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjucHRKSzVyPUOuPFY6PThizszN	NV3kRZB5W0GQR1XS
MV-4-11	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zZZ2lEPTB;ND6xN\|M{PCEQvF2=	NFzhNoJUSU6JRWK=
PA-1	Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTRwMkWyPUDPxE1?	MWHTRW5ITVJ?
EW-22	M{PRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFS4eFVKSzVyPUSuN\|U5PiEQvF2=	MWDTRW5ITVJ?
KASUMI-1	NVXvU3FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PiSGlEPTB;ND60NFExQSEQvF2=	MU\TRW5ITVJ?
LU-139	NUW5OVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\MTWM2OD12Lke1PFI6KM7:TR?=	M33XfnNCVkeHUh?=
SBC-1	NULuVFFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLNWJVpUUN3ME20MlgxQTB6IN88US=>	MXzTRW5ITVJ?
H4	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\uWmlEPTB;ND64PVQ1OyEQvF2=	Ml3nV2FPT0WU
EW-11	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWO5bnF[UUN3ME21MlA5ODd{IN88US=>	Ml;xV2FPT0WU
NBsusSR	NUS0eY1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILjSpBKSzVyPUWuNVIxPTVizszN	M4f1ZnNCVkeHUh?=
RPMI-8226	NITzdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPNdm93UUN3ME21MlE2OjR2IN88US=>	MkL6V2FPT0WU
DEL	NES1cphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTVwMkCwNFYh\|ryP	MYDTRW5ITVJ?
ES4	NXz3bYI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULlOWdIUUN3ME21MlUyOzh7IN88US=>	M4rqZnNCVkeHUh?=
GCT	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rUUGlEPTB;NT61Olg2PiEQvF2=	M2jJN3NCVkeHUh?=
NCI-H1048	M1fnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTVwOUeyO\|Mh\|ryP	M2XufHNCVkeHUh?=
NCI-SNU-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXXTWM2OD14LkCyNkDPxE1?	MXjTRW5ITVJ?
ES7	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTZwMEO1O\|ch\|ryP	Mn\rV2FPT0WU
SW982	NEH5VphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTZwMEmxN\|ch\|ryP	NEXKVIdUSU6JRWK=
L-363	NIDv[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLCdGtwUUN3ME22MlM{QTd2IN88US=>	MVTTRW5ITVJ?
HT-1080	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\qV3BKSzVyPU[uOFk3QDNizszN	MYfTRW5ITVJ?
HAL-01	M1nYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTZwNUGwPUDPxE1?	NVf1bnplW0GQR1XS
NB14	M3zIemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPSTXV3UUN3ME22MlY1ODN7IN88US=>	NUjPUYVsW0GQR1XS
EW-13	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWqw[ZI1UUN3ME22Mlc4PDJ2IN88US=>	MkTzV2FPT0WU
NY	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;wSZJKSzVyPU[uPVQ3ODVizszN	M{nBTHNCVkeHUh?=
NCI-SNU-5	NV7O[4FOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTdwMUC0N\|Mh\|ryP	Mo\hV2FPT0WU
MS-1	M{[zO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTdwMUe0PVQh\|ryP	MX\TRW5ITVJ?
EW-16	NGHaO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTdwM{G4OlEh\|ryP	M{jTbXNCVkeHUh?=
LU-65	NHvMdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTdwNEi0NVch\|ryP	NE\2bndUSU6JRWK=
HGC-27	MnjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTdwN{KxO\|Mh\|ryP	MYPTRW5ITVJ?
CTB-1	NXriToVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zhRmlEPTB;Nz63OlE4PSEQvF2=	MYjTRW5ITVJ?
5637	NUDPXGhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PyZWlEPTB;Nz65Nlg3KM7:TR?=	NUXwWGhiW0GQR1XS
U251	NV;aNJdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWe0PJo4UUN3ME23Mlk1ODF4IN88US=>	NUXjXVNbW0GQR1XS
HOS	NGK5U\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRThwMkOwNFch\|ryP	Mk\5V2FPT0WU
DOHH-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e0bWlEPTB;OD6yN\|U5KM7:TR?=	NFiyNphUSU6JRWK=
EW-1	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DSTmlEPTB;OD6zNFA5QCEQvF2=	NV\mT4lqW0GQR1XS
BV-173	NILlSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRThwNUW1OEDPxE1?	NIjsR3hUSU6JRWK=
8-MG-BA	NHq2T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXuTWM2OD16Lk[4PVg5KM7:TR?=	MlTIV2FPT0WU
NB69	NFXEflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRThwN{C5NlEh\|ryP	NILBWW9USU6JRWK=
NCI-H69	NEfGVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITHPJJKSzVyPUmuPVA6PjFizszN	MVnTRW5ITVJ?
RS4-11	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjnTWM2OD1zMT6yNlA5KM7:TR?=	M{XUcnNCVkeHUh?=
ONS-76	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLGTWM2OD1zMT6yPVQ4KM7:TR?=	MnrYV2FPT0WU
SF539	NH\0UHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPXVXVtUUN3ME2xNU41QDh7IN88US=>	MV3TRW5ITVJ?
HuO-3N1	NHnIUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXSTWM2OD1zMT61O\|k3KM7:TR?=	M1SzNnNCVkeHUh?=
NCI-H1651	NF3JRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;RcYl7UUN3ME2xNk4{OTF3IN88US=>	M4DhbHNCVkeHUh?=
KARPAS-45	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmOzTWM2OD1zMj6zO\|Yh\|ryP	MmG3V2FPT0WU
SK-NEP-1	M4T1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTF{LkS2NFkh\|ryP	MoHTV2FPT0WU
LAMA-84	M1HT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3qVopWUUN3ME2xN{4yODl3IN88US=>	NGnxcnZUSU6JRWK=
NCI-H1155	M2DjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjHb5puUUN3ME2xN{4zQDV4IN88US=>	MnjUV2FPT0WU
CTV-1	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zVU2lEPTB;MUOuOFQ2KM7:TR?=	NUfZTolLW0GQR1XS
QIMR-WIL	NInnemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF\|Lke4NVQh\|ryP	NVT3[\|J4W0GQR1XS
H9	NIrteGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHwco1KSzVyPUGzMlg1PzVizszN	MWjTRW5ITVJ?
SK-MEL-1	NELWfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzITWM2OD1zMz65N\|Q4KM7:TR?=	NUTGNnlQW0GQR1XS
HD-MY-Z	NUTHd2xYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\vd2lEPTB;MUSuNFY{PyEQvF2=	MWXTRW5ITVJ?
TI-73	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjaTWM2OD1zND6yN\|U3KM7:TR?=	NXrvNGpDW0GQR1XS
JVM-3	M37XbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTDTWM2OD1zNT61O\|E3KM7:TR?=	NGLnSFFUSU6JRWK=
D-247MG	MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe3RZdPUUN3ME2xOU42QTNizszN	NV;Ve2hDW0GQR1XS
VA-ES-BJ	NYLocm41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkSyTWM2OD1zNT62NFk4KM7:TR?=	MoDoV2FPT0WU
NOS-1	NIrKR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLzTWM2OD1zNT62OVIzKM7:TR?=	NHTzSoRUSU6JRWK=
MOLT-4	NGO4OnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnPZYtvUUN3ME2xOk44PTJizszN	NGPycopUSU6JRWK=
Mo-T	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXsPJJKSzVyPUG3MlA5PDlizszN	MV3TRW5ITVJ?
NCI-H1770	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXUTWM2OD1zNz6xOVQ{KM7:TR?=	MYXTRW5ITVJ?
COLO-320-HSR	NV;ERlBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zTZWlEPTB;MUeuNVgzPyEQvF2=	M3LKbHNCVkeHUh?=
TE-12	NHjw[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTF5LkewOVQh\|ryP	MlPZV2FPT0WU
NCI-H82	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjafnVKSzVyPUG3Mlg4OjhizszN	M4DXOXNCVkeHUh?=
NEC8	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTF6LkGzNVYh\|ryP	MYTTRW5ITVJ?
HSC-3	M130WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF6Lke0NVQh\|ryP	NFGzdoJUSU6JRWK=
NCI-H1092	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPIV3gxUUN3ME2xPE44PTl3IN88US=>	NWOwToRMW0GQR1XS
NCI-H292	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{XibWlEPTB;MUmuNFQ5QSEQvF2=	MlTmV2FPT0WU
L-428	M4D0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXuVHZKSzVyPUG5MlU2QSEQvF2=	MUXTRW5ITVJ?
LU-134-A	NYPLUW1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPUTWM2OD1zOT61O\|Ih\|ryP	MljLV2FPT0WU
GI-ME-N	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfJbVRFUUN3ME2xPU42PzR5IN88US=>	MojHV2FPT0WU
ALL-PO	NYH3OFh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDQZYh{UUN3ME2xPU42QTd{IN88US=>	MVfTRW5ITVJ?
D-283MED	NIPoNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF7LkmxOUDPxE1?	NFvzUHBUSU6JRWK=
D-423MG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnyTWM2OD1zOT65PVY4KM7:TR?=	MVfTRW5ITVJ?
CAKI-1	NXfkNIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPjNWdlUUN3ME2yNE4zOjF7IN88US=>	MVjTRW5ITVJ?
ETK-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnnXJRTUUN3ME2yNE4zPjF3IN88US=>	MmO5V2FPT0WU
G-402	M{fKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTJyLkWzN\|Qh\|ryP	NXXXN2tUW0GQR1XS
HL-60	M13QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofrTWM2OD1{MT6xOlE{KM7:TR?=	M1n0TXNCVkeHUh?=
A2058	NIfuTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTSVpJKSzVyPUKxMlQ1PzdizszN	NEn2flJUSU6JRWK=
CHP-212	NF;4NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTJzLkmwOVEh\|ryP	NHryO5RUSU6JRWK=
KY821	NH6wbmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\nTWM2OD1{MT65O\|Uh\|ryP	M{\lfHNCVkeHUh?=
TYK-nu	NFfVT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrwbYZsUUN3ME2yNk4xPjVzIN88US=>	M1vJZnNCVkeHUh?=
JVM-2	NEmybnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTqVYhKSzVyPUKyMlI6QDNizszN	MnvTV2FPT0WU
KU812	NGLYeXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV:yWJFTUUN3ME2yNk44OzF{IN88US=>	Mkj3V2FPT0WU
MKN28	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJ{LkmwNVUh\|ryP	MXTTRW5ITVJ?
ECC10	M3zKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPXcIRKUUN3ME2yN{44PDFizszN	M3\WZnNCVkeHUh?=
BHT-101	MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjHTWM2OD1{ND6wNFA5KM7:TR?=	NV[0NpVGW0GQR1XS
DU-4475	M2jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLkTWM2OD1{ND6zN\|M4KM7:TR?=	NX7xW5I5W0GQR1XS
769-P	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJ2Lki0OlYh\|ryP	MluyV2FPT0WU
HEC-1	NHHycYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmniTWM2OD1{NT60OFUh\|ryP	M1LtXXNCVkeHUh?=
MOLT-13	M4[2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlL1TWM2OD1{NT61N\|MyKM7:TR?=	NFv4ZoRUSU6JRWK=
8505C	NFixXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO5ZZJKSzVyPUK2MlQ6PzdizszN	Mnz0V2FPT0WU
GB-1	M2TwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLiTWM2OD1{Nj63NVc3KM7:TR?=	MlvSV2FPT0WU
SF126	NWrDSJNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJ4Lke2OFgh\|ryP	MnzTV2FPT0WU
A4-Fuk	M1zoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ5LkGyO\|Eh\|ryP	NWPreJBkW0GQR1XS
OVCAR-8	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTJ5LkG1N\|kh\|ryP	NUSwU4h2W0GQR1XS
NCI-H1304	M4HMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn4ZoxrUUN3ME2yO{42PCEQvF2=	MVXTRW5ITVJ?
GR-ST	MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jJcmlEPTB;MkiuNFQ4KM7:TR?=	MVvTRW5ITVJ?
G-401	M3:wTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{e4O2lEPTB;MkiuOVA6PiEQvF2=	M2DhW3NCVkeHUh?=
LXF-289	M3LteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnnVVduUUN3ME2yPE42PjVzIN88US=>	NV3Wb4JMW0GQR1XS
DBTRG-05MG	NXLlNXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJ6LkmyNFQh\|ryP	M4fYVHNCVkeHUh?=
YKG-1	NE\DfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nSeWlEPTB;MkmuPFY5KM7:TR?=	NWm0VJYyW0GQR1XS
GAMG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlm3TWM2OD1{OT65PVMh\|ryP	M2rOUXNCVkeHUh?=
HCT-116	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HSXmlEPTB;M{CuNFU1QCEQvF2=	MVrTRW5ITVJ?
S-117	MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTNzLkKyOVch\|ryP	MnrxV2FPT0WU
NCI-H1693	M37weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTN\|Lk[1OFIh\|ryP	NWDXR2x7W0GQR1XS
A427	M4\EOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfoRWJ6UUN3ME2zN{46QTd4IN88US=>	NUW3WYJPW0GQR1XS
HT-29	M2rDVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\ZPWZKSzVyPUO0MlYxOzJizszN	NIDHSZZUSU6JRWK=
P12-ICHIKAWA	M17vT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTN2Lke0PVEh\|ryP	NYLzclg{W0GQR1XS
CAL-51	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[0TWM2OD1\|NT6wO\|A6KM7:TR?=	MUDTRW5ITVJ?
Ramos-2G6-4C10	NWLuOmRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjJdIN[UUN3ME2zOU4zPDJ3IN88US=>	NYD3WpRHW0GQR1XS
SCH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTN4LkSxO\|Qh\|ryP	MVHTRW5ITVJ?
SK-MEL-24	M3nvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fRXmlEPTB;M{[uPVA1PCEQvF2=	MofEV2FPT0WU
SW1573	NX;sXZVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\EbHpKSzVyPUO4MlczOTZizszN	MXLTRW5ITVJ?
BALL-1	MlX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\4TWM2OD1\|OT6yNVI6KM7:TR?=	M3X5XXNCVkeHUh?=
BE-13	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\1PWlEPTB;M{muN\|I6KM7:TR?=	M2Th[nNCVkeHUh?=
GI-1	M4XWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fIO2lEPTB;M{muPFY1PyEQvF2=	Mn;1V2FPT0WU
GOTO	NXKwd4ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjpS2lKSzVyPUO5MlkyOzlizszN	Ml3xV2FPT0WU
A673	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfEdFJ5UUN3ME20NU4xOzR\|IN88US=>	MmrvV2FPT0WU
KG-1	NGXqbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTR\|LkO5OEDPxE1?	MnK5V2FPT0WU
GP5d	NW\qcY1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXKXoFKSzVyPUS0MlA3PjZizszN	MV\TRW5ITVJ?
MFM-223	MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;ZPIp[UUN3ME20OE4yOjJ6IN88US=>	M2XzOXNCVkeHUh?=
OAW-42	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTR2LkK2OFMh\|ryP	NEKySoZUSU6JRWK=
C8166	NHPlWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPmcXd1UUN3ME20OU4xQDJ{IN88US=>	MlK5V2FPT0WU
LU-99A	NETRdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGq0eoFKSzVyPUS2MlE{OjJizszN	M172S3NCVkeHUh?=
NCI-H23	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDMTWM2OD12Nj6xO\|g2KM7:TR?=	MUHTRW5ITVJ?
HO-1-N-1	NHLKcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfKSZZjUUN3ME20O{4xQTl6IN88US=>	MkLlV2FPT0WU
A3-KAW	NILQfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYD6OXFZUUN3ME20O{4yODB5IN88US=>	M1;QR3NCVkeHUh?=
CGTH-W-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTR5LkWwOlkh\|ryP	M3zEVHNCVkeHUh?=
DJM-1	NUjndZNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLjTWM2OD12Nz61OFE{KM7:TR?=	MWHTRW5ITVJ?
A101D	NIO5ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O0NGlEPTB;NEeuOlM2PyEQvF2=	NW\kUJVXW0GQR1XS
BB30-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LrZ2lEPTB;NEiuN\|A4OiEQvF2=	NIX6UGdUSU6JRWK=
T98G	NHvPWIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3OxfmlEPTB;NEiuOFY{OyEQvF2=	NXLJR2xGW0GQR1XS
NCI-H1573	M{LwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;TdmlEPTB;NEmuOFQ3OiEQvF2=	NH\ZfHBUSU6JRWK=
MEG-01	M3vPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq3XJlKSzVyPUS5Mlc1OTFizszN	NYSzdoRJW0GQR1XS
WM-115	NWnYRVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInpUGpKSzVyPUS5MlkzOjJizszN	NILRPGVUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	- Collapse Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

- Collapse

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Ku-0059436
Smiles	FC1=C(C=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1)C(=O)N4CCN(CC4)C(=O)C5CC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04298021	Not yet recruiting	Drug: AZD6738\|Drug: Durvalumab\|Drug: Olaparib	Bile Duct Cancer\|Chemotherapy Effect	Seoul National University Hospital	April 1 2020	Phase 2
NCT04330040	Not yet recruiting	Drug: Olaparib	Ovarian Cancer\|Breast Cancer	AstraZeneca	March 31 2020	Phase 4
NCT04005690	Recruiting	Drug: Cobimetinib\|Drug: Olaparib	Borderline Resectable Pancreatic Adenocarcinoma\|Locally Advanced Pancreatic Ductal Adenocarcinoma\|Metastatic Pancreatic Ductal Adenocarcinoma\|Resectable Pancreatic Ductal Adenocarcinoma\|Stage I Pancreatic Cancer AJCC v8\|Stage IA Pancreatic Cancer AJCC v8\|Stage IB Pancreatic Cancer AJCC v8\|Stage II Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8\|Stage IV Pancreatic Cancer AJCC v8	OHSU Knight Cancer Institute\|National Cancer Institute (NCI)\|Oregon Health and Science University	August 1 2019	Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281)